Medication Overuse Headache After TBI: Rebound Risk

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Medication overuse headache (MOH) is a paradoxical worsening of headache caused by frequent use of the very medications prescribed to treat it. TBI patients in personal injury cases face elevated MOH risk due to persistent post-traumatic headaches requiring ongoing analgesic use.

Medication overuse headache (MOH), also called rebound headache, is a secondary headache disorder that develops when acute headache medications are used too frequently -- typically more than 10-15 days per month for 3 or more months. In personal injury cases involving traumatic brain injury, MOH is a significant clinical concern because post-traumatic headaches are among the most common and persistent TBI symptoms, driving frequent analgesic use that can paradoxically worsen the headache condition.

• MOH develops through central sensitization of trigeminal pain pathways and downregulation of endogenous pain modulation systems when acute headache medications are used more than 10-15 days per month
• Opioids and combination analgesics (butalbital-containing products) carry the highest MOH risk, followed by triptans, then simple analgesics (NSAIDs, acetaminophen)
• Post-traumatic headache after TBI is the primary headache type in PI that progresses to MOH, affecting an estimated 30-50% of TBI patients with persistent headache
• Breaking the MOH cycle requires medication withdrawal (often producing 1-2 weeks of worsened headache), transition to preventive therapy, and careful documentation of the entire process
• LienScripts tracks analgesic fill frequency and days-supply patterns to identify MOH risk before it develops

The Pathophysiology of Rebound Headache

MOH is not simply a matter of "taking too much medicine." It represents a genuine neuroplastic change in the brain's pain processing circuitry:

Central Sensitization

Frequent activation of trigeminal nociceptive pathways by repeated analgesic use and withdrawal cycles produces central sensitization -- a state where the pain processing neurons in the trigeminal nucleus caudalis become hyperexcitable. Lower-intensity stimuli trigger pain responses, and the threshold for headache activation drops progressively.

Serotonergic Dysfunction

Chronic analgesic use disrupts central serotonergic tone. Serotonin is a key modulator of trigeminal pain processing, and its depletion through repeated medication cycles reduces the brain's endogenous pain suppression capacity. The patient becomes increasingly dependent on exogenous analgesics to achieve pain levels that their own serotonergic system previously maintained.

Cortical Spreading Depression

Research suggests that MOH may increase the frequency of cortical spreading depression events -- the wave of neuronal depolarization that underlies migraine aura and triggers the trigeminal-vascular pain cascade. The result is more frequent headache episodes requiring more medication, creating a self-reinforcing cycle.

Medication-Specific MOH Risk in PI

Different analgesic classes carry different thresholds for MOH development:

Highest Risk: Opioids and Butalbital Combinations

Opioids carry the highest MOH risk, with the threshold at approximately 10 days per month of use. The mu-receptor adaptations that produce opioid dependence parallel and compound the central sensitization that drives MOH. Butalbital-containing combinations (Fioricet, Fiorinal) carry similar risk through barbiturate-mediated GABA-A adaptations.

For PI patients receiving hydrocodone or oxycodone for post-traumatic headache combined with musculoskeletal pain, the headache-specific MOH risk is often overlooked because the opioid is considered a "pain medication" rather than a "headache medication." The pathophysiology does not distinguish -- frequent opioid use for any indication can produce MOH in a patient with an underlying headache disorder.

Moderate Risk: Triptans

Triptans (sumatriptan, rizatriptan) prescribed for post-traumatic migraine carry MOH risk at approximately 10 days per month. Their 5-HT1B/1D agonist activity, when applied repeatedly, produces adaptive changes in serotonin receptor sensitivity that perpetuate the headache cycle.

Lower (But Real) Risk: Simple Analgesics

NSAIDs and acetaminophen carry MOH risk at approximately 15 days per month of use. While the risk threshold is higher, many PI patients exceed this threshold because NSAIDs are perceived as "safe" and are taken daily for ongoing pain management.

MOH in the Context of Post-Traumatic Headache

Post-traumatic headache (PTH) after TBI creates a uniquely high-risk scenario for MOH development:

Persistence of PTH

Post-traumatic headaches persist beyond 3 months in 30-50% of TBI patients, meeting the ICHD-3 criteria for persistent PTH. This prolonged headache duration drives sustained analgesic use that exceeds MOH thresholds.

Multiple Pain Sources

TBI patients in PI cases often have concurrent musculoskeletal injuries (cervical strain, lumbar pain) that independently require analgesic therapy. The combined analgesic consumption for headache plus musculoskeletal pain can easily exceed MOH thresholds even when the headache-specific use alone would not.

Cognitive Impairment

TBI-related cognitive impairment may reduce the patient's ability to track medication frequency and recognize the developing pattern of medication overuse. The gradual transformation from episodic headache to chronic daily headache with medication overuse can go unrecognized until established.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The transition from post-traumatic headache to medication overuse headache is clinically subtle. The patient reports that headaches are getting worse. The natural response is to take more medication. But the increased medication frequency is itself driving the worsening. Recognizing this cycle requires pharmacy-level monitoring of fill patterns over time -- precisely the kind of longitudinal data the LienScripts platform captures."

Breaking the MOH Cycle

Treatment of MOH requires discontinuation of the overused medication -- which initially produces a temporary worsening of headache (withdrawal headache) before improvement. The withdrawal management approach depends on the medication class:

Opioid and Butalbital Withdrawal

These require gradual tapering due to physical dependence risk. Abrupt discontinuation of daily opioids or butalbital can produce withdrawal symptoms beyond headache worsening (autonomic instability, seizure risk with butalbital). A supervised taper over 2-4 weeks with transition to preventive medications is standard.

Triptan Withdrawal

Triptans can generally be discontinued abruptly. The withdrawal headache period is typically 7-10 days, after which headache frequency and severity begin to improve.

NSAID/Acetaminophen Withdrawal

Simple analgesics can be discontinued abruptly. A bridging strategy using a short course of corticosteroids (prednisone taper) or a long-acting NSAID (naproxen scheduled twice daily) may ease the transition.

Transition to Preventive Therapy

During and after the withdrawal period, preventive medications are initiated:

• Topiramate for post-traumatic migraine prevention
• Amitriptyline for tension-type post-traumatic headache
• Propranolol or verapamil for migraine frequency reduction
• CGRP monoclonal antibodies (erenumab, galcanezumab) for refractory cases

Documentation Value for PI Cases

MOH documentation strengthens PI cases in several ways:

Injury severity evidence: The development of MOH from post-traumatic headache documents that the TBI produced headaches severe and persistent enough to drive medication overuse -- a marker of significant head injury impact.

Treatment complexity: The MOH cycle-breaking process (medication withdrawal, bridging therapy, preventive medication initiation, monitoring) represents a distinct treatment phase that extends the documented treatment timeline.

Pharmacist intervention evidence: Identification of MOH risk through fill pattern monitoring demonstrates expert pharmaceutical care. LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages that includes analgesic utilization patterns and MOH risk assessments.

Ongoing treatment needs: A patient who develops MOH from post-traumatic headache requires ongoing preventive medication management -- potentially indefinitely -- adding a future medical expense component to the damages picture.

Prevention: The Role of Pharmacy Monitoring

The most effective approach to MOH is prevention through prospective monitoring of analgesic use patterns. The LienScripts platform tracks fill dates, days supply, and medication frequency for all PI patients. When a headache medication approaches the 10-15 day monthly threshold, pharmacist intervention can alert the prescriber before MOH develops -- preventing the condition rather than treating it after establishment.

This proactive monitoring is precisely the kind of value-added pharmaceutical care that distinguishes clinical pharmacy lien services from simple prescription dispensing.